85002-74-0

Basic information

• Product Name: 1-(CyclopropylMethoxy)-4-nitrobenzene
• Synonyms: 1-(CyclopropylMethoxy)-4-nitrobenzene
• CAS NO: 85002-74-0
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.19924
• Mol File: 85002-74-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 9-10 °C(Solv: ethyl ether (60-29-7); water (7732-18-5))
• Boiling Point: 327.2±15.0 °C(Predicted)
• Appearance: /
• Density: 1.250±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-(CyclopropylMethoxy)-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(CyclopropylMethoxy)-4-nitrobenzene(85002-74-0)
• EPA Substance Registry System: 1-(CyclopropylMethoxy)-4-nitrobenzene(85002-74-0)

Safety Data

• Hazardous Substances Data: 85002-74-0(Hazardous Substances Data)

Usage

General Description

1-(CyclopropylMethoxy)-4-nitrobenzene, also known as CPNB, is a chemical compound with the molecular formula C10H11NO3. It is a nitrobenzene derivative with a cyclopropylmethoxy group attached to the 1-position of the benzene ring. CPNB is a yellow crystalline powder that is commonly used as a precursor for the synthesis of various pharmaceuticals and agrochemicals. It is also utilized in research and development laboratories as a building block for the creation of new chemical compounds. CPNB has potential applications in the field of medicinal chemistry and drug discovery due to its unique structure and properties. Additionally, it is important to handle CPNB with care as it is toxic and may cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 2516-33-8 Cyclopropylmethanol 
• 100-00-5 4-chlorobenzonitrile 
• 100-02-7 4-nitro-phenol 
• 7051-34-5 cyclopropylcarbinyl bromide 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 74773-28-7 5-(4-Cyclopropylmethoxy-benzyl)-thiazolidine-2,4-dione 
• 85003-34-5 2-Chloro-3-(4-cyclopropylmethoxy-phenyl)-propionic acid methyl ester 
• 122828-48-2 4-(cyclopropylmethoxy)benzenamine 

Relevant articles and documents

Aryl Ether Syntheses via Aromatic Substitution Proceeding under Mild Conditions

In this study, mild conditions for aromatic substitutions during the syntheses of aryl ethers were developed. In the reaction conditions, the choices of solvent, base, and the sequence for the addition of the reagents proved important. A wide variety of alcohols were used directly as nucleophiles and smoothly reacted with aryl chlorides that possessed either a nitro or a cyano group at either the ortho- or para-position. Controlled experiments we performed suggested that the reaction underwent a charge-transfer process mediated by a combination of DMF and tert-BuOK.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

New β-alanine derivatives are orally available glucagon receptor antagonists

A weak human glucagon receptor antagonist with an IC50 of 7 μM was initially found by screening of libraries originally targeted to mimic the binding of the glucagon-like peptide (GLP-1) hormone to its receptor. Optimization of this hit for binding affinity for the glucagon receptor led to ligands with affinity in the nanomolar range. In addition to receptor binding, optimization efforts were made to stabilize the molecules against fast metabolic turnover. A potent antagonist of the human human glucagon receptor was obtained that had 17% oral availability in rats with a plasma half-life of 90 min. The major metabolites of this lead were identified and used to further optimize this series with respect to pharmacokinetic properties. This final optimization led to a potent glucagon antagonist that was orally available in rats and dogs and was efficacious in lowering blood glucose levels in a diabetic animal model.